Evidence Capital: Why the Economic Value of Verified Data Increases Through Computational Recombinations

A DataUniversa White Paper, by John F. Groom, Founder

Executive Summary

Traditional accounting views data as an asset that depreciates over time. Traditional research often views datasets as collections assembled to answer a specific question. Both perspectives underestimate the long-term economic value of high-quality evidence.

This paper proposes a different framework.

A verified evidence object, with clear provenance, broad consent, standardized structure, and rich metadata, is not merely information. It is Evidence Capital.

Unlike most physical assets, Evidence Capital does not derive its value from a single intended purpose. Instead, its value grows as new computational methods, algorithms, and analytical frameworks discover previously unknown ways to combine existing evidence.

The initial cost lies in creating trustworthy evidence. The subsequent creation of new products, indices, predictive models, and decision systems becomes progressively less expensive because they are built upon an existing foundation of trusted observations.

The economic implication is profound:

The long-term value of an evidence object is determined not only by the questions it answers today, but by the future questions it becomes capable of answering.

1. The Traditional Model

Most organizations collect data for a specific purpose.

Examples include:

• Conducting a clinical trial.
• Measuring employee satisfaction.
• Performing a customer survey.
• Capturing exercise performance.

Once the original study concludes, much of the remaining value is lost because the data were collected narrowly, with limited consent, inconsistent provenance, or incomplete metadata.

The data answered one question. Its useful life largely ended.

2. The Evidence Capital Model

DataUniversa proposes a fundamentally different model.

Rather than collecting data to answer one predefined question, the objective is to create durable, reusable evidence objects that can support many future questions.

Each evidence object should possess:

• Verified provenance.
• Broad legal consent.
• Standardized structure.
• Rich metadata.
• High technical quality.
• Long-term interoperability.

Once these characteristics exist, the evidence becomes computationally reusable. The original acquisition cost is incurred once. Future value creation increasingly occurs through computation rather than recollection.

3. Acquisition Costs Versus Recombinations

These activities have fundamentally different economics.

The expensive component is creating trusted evidence.

The inexpensive component is discovering new ways to use it.

4. From Data to Evidence Capital

Consider a certified Global Fast Fit (GFF) Pro video. The original direct capture cost was approximately $90.

Including management, salaries, overhead, equipment, travel, consent administration, and quality assurance, the true organizational cost may approach $250.

Viewed traditionally, this appears expensive. Viewed as Evidence Capital, however, the economics are entirely different.

The $250 did not purchase a single fitness score. It purchased a reusable evidence object.

5. Recombinations Create New Products

Initially, a GFF Standard video supports one benchmark.

Later, the same evidence contributes to:

• Global Fast Fit Standard
• Age-adjusted performance norms
• Longitudinal performance tracking
• AI training datasets
• Movement pattern recognition
• Clinical comparisons
• Fall-risk prediction
• Functional decline models
• Research datasets
• Commercial licensing

No additional participant must be recruited. No additional video must be collected. The original observation continues producing value.

6. SALI: A First-Generation Recombinational Product

SALI demonstrates this principle.

Rather than requiring a completely new acquisition process, SALI combines existing evidence from:

• Global Fast Fit Standard
• LR 250-meter running performance

Neither dataset was created specifically for SALI.

The value emerged from computational recombination. The acquisition costs had already been paid. The new product required analysis rather than recollection.

7. The SCE Composite

The same principle applies to the Simple Core Evaluation (SCE).

Rather than designing an entirely new testing protocol, SCE recombines existing evidence including:

• Grip strength
• Push-ups
• Five-repetition sit-to-stand
• Single-leg balance
• Eyes-closed balance
• Overhead reach

Each individual measurement has independent value.

Together they create a new functional assessment whose acquisition cost is only marginally greater than collecting the individual components separately.

Again, the value comes primarily from computation rather than additional evidence collection.

8. Higher-Order Recombinations

The process does not end with first-generation products. Derived metrics themselves become new computational building blocks.

Examples include:

Primary Evidence

• GFF video
• LR running performance
• Grip strength
• Consent
• Demographics

↓

First-Generation Products

• GFF Standard
• SALI
• SCE Composite

↓

Second-Generation Products

• Functional resilience indices
• Disease-specific predictors
• Intervention effectiveness scores
• AI coaching models
• Personalized risk trajectories

↓

Third-Generation Products

• Clinical decision support
• Insurance models
• Public health planning
• Workforce capability assessment
• Previously unknown applications

Each successful recombination expands the number of future recombinations.

The productive capacity of the evidence library grows over time.

9. Computational Option Value

The future applications of today's evidence cannot be fully predicted.

When GPS satellites were launched, few anticipated ride-sharing, smartphone navigation, precision agriculture, or food delivery platforms. The infrastructure enabled unforeseen industries. Evidence Capital behaves similarly. High-quality evidence preserves the option to answer questions that have not yet been conceived.

This creates what may be called Computational Option Value.

Organizations are investing not only in current analyses but also in preserving future analytical possibilities.

10. Why Provenance Matters

Poor-quality data have limited recombinational value.

Every new application requires additional validation.

By contrast, evidence with:

• verified provenance,
• broad consent,
• standardized collection,
• rich metadata,

can be recombined repeatedly with substantially lower transaction costs.

Provenance therefore functions as an economic multiplier rather than merely a compliance requirement.

11. Implications for the Data Acquisition Market

The Data Acquisition Market (DAM) exists to create Evidence Capital efficiently.

Each acquisition transaction represents the creation of another reusable computational asset.

Rather than paying simply for labor, DAM compensates contributors for producing durable evidence capable of generating future products.

This also forces explicit valuation.

Instead of paying salaries for broad job descriptions, organizations must determine the economic value of individual evidence-producing activities:

• recruiting participants,
• obtaining consent,
• collecting videos,
• performing verification,
• conducting follow-ups,
• documenting interventions.

The result is a transparent economic model for evidence creation.

12. Strategic Implications

As an evidence library grows:

• acquisition costs increase approximately linearly,
• storage costs remain relatively low,
• computational capability continues improving,
• the number of possible recombinations expands dramatically.

Not every possible recombination will prove valuable. However, every new validated recombination becomes another building block for future innovation.

The result is an expanding ecosystem of computational assets whose productive capacity grows over time.

Unlike many traditional assets, the economic value of Evidence Capital can increase without recollecting the original observations.

Conclusion

The primary purpose of data acquisition is not to answer today's questions. It is to create durable Evidence Capital capable of answering tomorrow's questions.

Global Fast Fit, SALI, the Simple Core Evaluation, and future analytical products demonstrate this principle.

Each new computational product increases the return on prior evidence acquisition while simultaneously expanding the opportunity space for future discoveries. The value of Evidence Capital therefore lies not only in what it already knows, but in what it will eventually make possible.

Organizations that recognize this distinction will increasingly compete not on the size of their datasets, but on the quality, provenance, interoperability, and computational reuse of their evidence.

Evidence collected once can generate value repeatedly. That is the central economic advantage of Evidence Capital.